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Aim: Hypnagogic and hypnopompic hallucinations are characteristic symptoms of nar-
colepsy, as are excessive daytime sleepiness, cataplexy, and sleep paralysis. Narcolepsy
patients may also experience daytime hallucinations unrelated to sleep–wake transitions.
The effect of medication on hallucinations is of interest since treatment of narcolepsy may
provoke psychotic symptoms. We aim to analyze the relation between sodium oxybate
(SXB) treatment and psychotic symptoms in narcolepsy patients. Furthermore, we analyze
the characteristics of hallucinations to determine their nature as mainly psychotic or hypn-
agogic and raise a discussion about whether SXB causes psychosis or if psychosis occurs
as an endogenous complication in narcolepsy.
Method: We present altogether four patients with narcolepsy who experienced psy-
chotic symptoms during treatment with SXB. In addition, we searched the literature for
descriptions of hallucinations in narcolepsy and similarities and differences with psychotic
symptoms in schizophrenia.
Results: Three out of four patients had hallucinations typical for psychosis and one had
symptoms that resembled aggravated hypnagogic hallucinations. Two patients also had
delusional symptoms primarily associated with mental disorders. Tapering down SXB was
tried and helped in two out of four cases. Adding antipsychotic treatment (risperidone)
alleviated psychotic symptoms in two cases.
Conclusion: Psychotic symptoms in narcolepsy may appear during SXB treatment. Hal-
lucinations resemble those seen in schizophrenia; however, the insight that symptoms
are delusional is usually preserved. In case of SXB-induced psychotic symptoms or
hallucinations, reducing SXB dose or adding antipsychotic medication can be tried.
Keywords: xyrem, sodium oxybate, gamma hydroxybutyrate, psychosis, hallucinations, narcolepsy, schizophrenia,
sleep disorders
INTRODUCTION
Hypnagogic and hypnopompic hallucinations (HG, HP) are part
of the classic narcolepsy tetrad (1). The other three are excessive
daytime sleepiness (EDS), cataplexy (CPL), and sleep paralysis
(SP) but other symptoms such as fragmented sleep are also com-
mon. Psychiatric comorbidity is frequently seen but there is little
information about the prevalence of psychotic symptoms in nar-
colepsy. The first cases of psychosis in narcolepsy were described
in the early twentieth century (2, 3). In a case series study of
Roy, 1 out of 20 narcolepsy patients had schizophrenia-like psy-
chosis (4). In a more recent Taiwanese series, 9.8% of narcoleptic
children developed schizophrenia at an average age of 2.5 (±1.8)
years after narcolepsy onset (5). Some of these reports most likely
presented iatrogenic amphetamine psychoses. However, there are
also recent reports about psychotic symptoms in narcolepsy not
related to medications suggesting possible link between narcolepsy
and schizophrenia (5, 6).
ETIOLOGICAL SIMILARITIES IN NARCOLEPSY AND
SCHIZOPHRENIA
Type 1 narcolepsy is caused by selective loss of hypocretin pro-
ducing cells in the lateral hypothalamus area (7). The hypocre-
tin system has a complex interplay with the dopaminergic and
also serotonergic systems involved in schizophrenia (8). It also
harbors extensive contacts within the central nervous system
(CNS) including projections to the ventral tegmental area (VTA),
main CNS regions involved in motivation and reinforcement
processes (9). Hypocretin neurons are also abundantly connected
to the prefrontal cortex (PFC), which together with the VTA
play an important role in the pathophysiology of schizophre-
nia (8). Consequently, the hypocretin system has been shown to
have a bearing not only on narcolepsy but also on schizophre-
nia, mood, anxiety, addiction, and eating disorders (10). Thus,
the role of the hypocretin system in the field of psychiatry is of
interest.
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Type 1 narcolepsy is thought to be an autoimmune dis-
order (11). This is suggested, e.g., by a strong link with
HLA class II DQB1*06:02 allele, association with AS03 adju-
vanted H1N1-vaccination campaign during winter 2009–2010
and a recent immunological findings (11, 12). However, disease-
specific autoantibodies remain to be found. Recently, there has
been increased interest in anti-neuronal antibodies such as N -
methyl-d-aspartate receptors (NMDAr) antibodies, because they
can produce severe but treatable limbic encephalitis. A Japan-
ese group found anti-NMDAr antibodies in 4 of 51 schiz-
ophrenic patients. They reported also three of five hypocre-
tin deficient narcolepsy patients with severe psychosis (13).
Immunomodulatory treatment in narcolepsy has provided rather
poor results (14).
Interestingly, schizophrenia shares some genetic background
concerning HLA with diseases known to be connected to the
immune system (for example, diabetes, RA, SLE, asthma, and
psoriasis) (15). This raises a question about a possible autoim-
mune/inflammatory background in schizophrenia, which also
typically has an onset in young age, similar to narcolepsy and
many other autoimmune diseases.
PSYCHOTIC SYMPTOMS AND HALLUCINATIONS IN
SCHIZOPHRENIA AND NARCOLEPSY
The phenomenology of hallucinations has been studied and it
seems possible to separate hallucinations from narcolepsy and
schizophrenia, respectively, from this point of view. Fortuyn
et al. compared hallucinations in narcolepsy and schizophrenia
by using semi-structured SCAN 2.1 interview (16). They found
that hallucinations in narcolepsy are more commonly non-verbal,
multimodal, hypnagogic, and hypnopompic in nature, while in
schizophrenia hallucinations tend to be verbal, discussing, com-
menting, and without insight of delusion and very rarely occurring
at sleep–wake transitions (Figure 1).
Positive psychotic symptoms such as delusions and hallucina-
tions seem to be related to specific areas of the brain. Impairment
of the PFC function causes disinhibited dopaminergic activity
in the mesolimbic pathway that originates from the VTA and
projects to various regions of the limbic system like nucleus
accumbens (17).
Negative symptoms are on the other hand associated with
hypoactivity of mesocortical dopaminergic projections from the
VTA to the PFC (18). We have not found any prior studies aim-
ing to find negative psychotic symptoms in narcolepsy. Given the
prevalence of positive symptoms and their close structural ori-
gin to that of the negative symptoms, there is at least a potential
that negative symptoms also occur with increased incidence in
narcolepsy. Major depressive disorder and social anxiety disorder
were found in 20% of patients with narcolepsy (19). Since depres-
sion can cause several of the negative symptoms and cognitive
dysfunction known from schizophrenia, identifying true negative
symptoms may be a challenge in narcolepsy.
FIGURE 1 | Patterns of hallucinations based on Science class
analysis for schizophrenic patients, narcolepsy patients, and
healthy controls. Adopted with permission from Fortuyn et al. (16). They
used SCAN 2.1 interviews to compare psychotic symptoms between 60
patients with narcolepsy, 102 with schizophrenia, and 120 matched
population controls.
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PHARMACOTHERAPY
Narcolepsy can be treated pharmacologically, but unfortunately
no curative treatments exist. The natural progression of the dis-
ease is variable and often the disability can be substantial. Aspects
of concern here are fatigue, CPL, disturbed night rest with hyp-
nagogic/hypnopompic hallucinations and frequent awakenings,
memory problems, depression, social isolation, and suppressed
emotions to avoid CPL.
Sodium oxybate (SXB) is a medication that is used more and
more in treatment of narcolepsy. It is helpful in treatment of CPL,
disturbed nocturnal sleep and daytime sleepiness. Incidence of
narcolepsy was increased especially in Finland, Sweden, Norway,
Ireland, and England after the swine fly pandemic and Pandemrix
vaccinations. The increase was noted especially among children
and young adults and there was a high demand for an effi-
cient treatment in severe cases (20–23), increasing use of Xyrem
in patients with Pandemrix-related narcolepsy. Xyrem is usually
well tolerated, but both psychosis and depression are described as
possible adverse effects of this drug (6, 24–26).
Sodium oxybate is a sodium salt of gamma-aminobuyric acid
(GABA) derived gamma-hydroxybutyric acid (GHB), which is
also present in the normal human CNS. Effects of SXB are medi-
ated via GABAb receptors and specific GHB receptors especially
in the hippocampus, neocortex, and thalamus (27). It may have
an effect on other neurotransmitter systems including glutamate,
serotonin, acetylcholine, and growth hormone. For example, it
induces increased slow wave sleep and short-term anterograde
amnesia (28). In vitro studies have shown that through GABAb
receptors, GHB may also have a bidirectional effect on dopamin-
ergic neurons in the VTA (29). At lower concentrations, GHB
usually inhibits GABAergic neurons in theVTA causing an increase
in dopamine output while at higher concentrations it has the
opposite effect via hyperpolarization of VTA neurons.
With the background described above, we believe that it is
of great interest to investigate the character of psychotic symp-
toms in detail above all since patients with narcolepsy may have
psychosis like symptoms that can sometimes transform into a psy-
chosis. Also, one must consider that in cases of severe narcolepsy
with intense symptoms including hypnagogic/hypnopompic hal-
lucinations there may be a benefit from treating the condition
with this drug, which may seem controversial at a first glance.
We therefore raise the question about what this adverse effect
actually is?
We present four cases with psychosis occurring after the intro-
duction of SXB, with different strategies of handling the problem,
and discuss the bearing on the characteristics of the disease as well
as of schizophrenia. Demographics of the patients are presented
in Table 1. None of them had any personal or family history of
psychiatric diseases.
CASE 1
A 37-year-old woman was referred to a sleep clinic. She was diag-
nosed with narcolepsy (type 1) 10 years earlier (see Table 1).
Symptoms included EDS, CPL, HG, and SP. Interestingly, this
patient had a history of several diseases related to autoimmunity:
asthma, psoriasis, generalized arthritis with edema and severe joint
rigidity, chronic tubulointerstitial nephritis, and discoid lupus.
Table 1 | Demographics of the patients.
ID Case 1 Case 2 Case 3 Case 4
Age at onset ~27 20.4 19.4 16.9
Age at dg 28.3 23.5 19.6 17.6
Gender Female Male Female Female
Hcrt (pg/ml) ND 0 0 0
DQB1*06:02 Pos Pos Pos Pos
MSL (min) 10 1 0 4.5
SOREMPs 3/5 2/4 2/4 3/5
Height 182 173 178 185
Weight 90 65 72 71
BMI (kg/m2) 27.17 21.72 22.72 20.75
CPL per week 30 70 2
ESS 14 24 15
HG Yes Yes Yes Yes
SP Yes No Yes No
NM Yes Yes Yes Yes
DNS Yes Yes Yes Yes
PDRX assoc No No No Yes (delay 486 days)
RBD No Yes Yes No
RLS No No No No
Date of onset October 2007 April 2009 April 2011
Brain MRI Normal Normal Normal Normal
Hcrt, hypocretin; MSL, mean sleep latency in multiple sleep latency test;
SOREMPs, number of sleep onset REM sleep periods in multiple sleep latency
test and number of registrations; BMI, body mass index; ESS, Epworth sleepi-
ness scale; HG, hypnagogic hallucinations; SP, sleep paralysis; NM, nightmares;
DNS, disturbed nocturnal sleep; PDRX assoc, whether the case is H1N1-
vaccination associated or not; RBD, REM sleep behavior disorder; RLS, restless
legs syndrome, ND, not done.
She had received a short cyclosporine treatment for her arthritis
1 year before the diagnosis of narcolepsy. She was also taking tra-
madol (centrally acting analgesic) for neck pain. Narcolepsy had
been treated for years with amphetamine, which was discontin-
ued because of lack of effect and adverse side effects. SXB was
initiated at 4.5 g per night divided in two doses. After 2 months,
she reported satisfying results regarding the full tetrad of symp-
toms and the SXB dose was increased to 6 g per night. After a total
of 7 months with SXB, tramadol was restarted because of pain
relapse. Around this time the patient started experiencing para-
noid daytime auditory hallucinations: specifically, either neighbors
arguing or a voice saying demeaning or commanding things. SXB
was gradually reduced and risperidone started to treat the psy-
chosis. Anxiety and CPL were treated with sertraline. Still, she
was admitted due to the psychosis. Risperidone was increased to
1.5 mg daily and SXB continued but at doses ranging from 2 to
4 g per night. Psychotic symptoms improved. Seven months later,
SXB was once again increased to 6 g per night though she still had
“mild” auditory hallucinations.
CASE 2
A 23-year-old man was diagnosed with narcolepsy (type 1) after
a complete investigation. Symptoms included EDS and CPL. He
also reported REM sleep behavior disorder. Total sleep time per
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night was 8–11 h. He was soon started on SXB, which was gradually
increased to 8.5 g per night divided into two doses. The disorder
was also treated with 100 mg modafinil twice daily. As soon as SXB
was initiated, he started to suffer from daytime hallucinations. At
home, he could hear speech from the other side of the wall; outside,
voices would discuss him, usually in a malevolent tone. Because of
this, he was started on risperidone, which helped immediately, at
a dose of 1 g daily. SXB was continued in the same dosage. After
this, he recognized that the hallucinations were not real but still
found them bothering.
CASE 3
A 19-year-old woman was diagnosed with narcolepsy (type 1) after
a complete investigation. Symptoms included EDS, CPL, HG, and
SP. She slept on average 7 h per night. She was initially treated with
100 mg modafinil twice daily. Due to lack of effect, SXB at a dose
of 4.5 g per night was also started. The cataplexies became milder
but soon she started to have frightening, vivid dreams, and hallu-
cinations. She heard the buzzing of bees entering the house and
loud noises, and experienced needling and numbness in her body.
She sometimes dreamed that an intruder sat on her back, stabbing
her in the neck with a knife. During the daytime, she had visions of
a man in a ditch. SXB treatment was modified so that she did not
take the first dose, which reduced nightmares and hallucinations
while going to bed. Unfortunately, SXB’s effect on daytime CPL
was also reduced.
CASE 4
A 17-year-old girl was diagnosed with narcolepsy (type 1) after
a complete investigation. Symptoms included EDS and CPL. She
had suffered aCampylobacter jejuni infection some months earlier
and had received the Pandemrix H1N1-vaccine 2 years before the
diagnosis. Modafinil helped her EDS, but she experienced CPL
on average twice a day. Thus, SXB was started at a dose of 4.5 g
per night. Her disturbed sleep was somewhat alleviated but when
the dose was increased to 7 g per night she started having hallu-
cinations, voices in her head as if men were saying their thoughts
aloud. For instance, one might tell her that a faucet was running.
She was started on escitalopram 5 mg daily and later olanzapine
2.5 mg per night. Modafinil was replaced with methylphenidate,
which did not help. After stopping SXB, hallucinations decreased
markedly. Because olanzapine caused weight gain, it was replaced
with 0.5–1.0 g of risperidone daily. This reduced hallucinations
so she was able to continue her studies. She wanted to try SXB
again because it had marked effect on poor sleep and CPL. After
restarting SXB hallucinations returned but increased risperidone
dose to 1.5 alleviated them. Her total sleep time in two different
actigraphy recordings was on average 7.5 and 9.9 h. Changes in
sleep time did not affect psychotic symptoms.
DISCUSSION
Narcolepsy is a life-long and often disabling disorder. The psy-
chiatric comorbidity in narcolepsy includes, e.g., symptoms of
depression, anxiety, eating disorders, and psychotic like symptoms
(16). Schizophrenia might be overrepresented in narcolepsy (5,
19). Age of onset in narcolepsy is usually in adolescence, around
age of 15 years. Severe illness among other concurrent psychophys-
iological and psychosocial factors and the end of puberty could
dispose to psychiatric disorders. Efficient treatment early from the
beginning of the disease is needed even if it is only symptomatic.
SXB has proven to be the very efficient and useful in adult nar-
colepsy and it seems to be safe and efficient also in treating children
and adolescents. There are, however, some aspects to be considered
such as a risk of psychotic symptoms. We believe that discussion
and sharing the knowledge about the adverse effects experienced
by the patients is valuable for everyone treating these patients. It
is often difficult to separate if the symptoms of the patients are
due to the disease per se or are they caused by adverse effects of a
drug. Furthermore, if the symptoms are adverse effect, which drug
is causing them? Our patient no. 1 had been using centrally act-
ing analgesic tramadol affecting serotonin, norepinephrine, and
µ-receptors. In our opinion, it was not the cause of the psychotic
symptoms but it cannot be ruled out that it would have some
minor effect. However, we are not aware of any published cases of
tramadol induced psychoses, and only few case reports of tramadol
withdrawal induced psychosis. Our case did not have serotonin
syndrome either. In our opinion, it is unlikely that psychosis could
have been induced by introduction of tramadol.
In our patients, tapering down SXB was tried and proved to be
efficient in reducing hallucinations but with the cost of increase in
other symptoms. Adding antipsychotic treatment can be tried but
the benefits and downsides of the treatment must be carefully con-
sidered. Adverse drug effect of antipsychotic medications should
preferably not be seen. In most cases,we tried risperidone but other
agents could be tried as well. Aripiprazole might be somewhat
less sedating and have less weight gain than other antipsychotics
(30). Unlike other antipsychotics, it is a D2-receptor partial ago-
nist acting as functional antagonist in brain areas of high levels
of dopamine and an agonist in regions with low dopamine con-
centration (31). No comparative studies have been done, however,
so this is pure speculation at the moment. More information is
needed of psychotic symptoms in narcolepsy regardless of if they
are caused by medication or not.
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